Skip to content

US · CPIX · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Cumberland Pharmaceuticals Inc. (CPIX) intrinsic value and stock valuation

$5.84as of 2026-11-21 · Mkt cap 113.12M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Cumberland Pharmaceuticals Inc. DCF and intrinsic value

InvestorsCraft values CPIX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CPIX’s statements →

Cumberland Pharmaceuticals Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Nashville, TN 37203 cumberlandpharma.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$44.5M+3.5% 5y CAGRd
20112025
Net income
-$-2.84M
20112025
Free cash flow
$4.83M+7.9% 5y CAGRd
20112025
Total equity
$24.5M-12.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$44.5M$37.9M$39.6M$42M$36M
Operating income-$-2.79M-$-6.43M-$-9.55M-$-5.7M-$-7.68M
Net income-$-2.84M-$-6.48M-$-6.28M-$-5.57M-$-3.51M
EPSd-$-189.84K-$-460.88K-$-439.16K-$-382.55K-$-235.57K
Operating cash flow$4.93M-$-610K$6.09M$8.45M$6.34M
Capital expenditure-$-100K-$-180K-$-450K-$-2.07M-$-350K
Free cash flow$4.83M-$-790K$5.64M$6.38M$5.99M
Total assets$76.8M$75.6M$81.8M$92.9M$84.5M
Total debt$10.2M$20.6M$18.4M$21M$16.1M
Net debt-$-1.26M$2.61M$110K$1.2M-$-10.98M
Total equity$24.5M$22.6M$29.3M$36M$42.6M
Cash and short-term investments$11.4M$18M$18.3M$19.8M$27M
Income statement
20252024202320222021
Revenue$44.5M$37.9M$39.6M$42M$36M
Cost of revenue$6.67M$6.59M$6.07M$9.12M$8.81M
Gross profit$37.9M$31.3M$33.5M$32.9M$27.2M
Research and development expenses$5.57M$4.82M$5.83M$6.69M$5.68M
Selling, general and administrative expenses$31.1M$28.2M$29.1M$26.8M$24.8M
Other expenses$4.03M$4.75M$8.1M$5.07M$4.37M
Operating expenses$40.7M$37.7M$43M$38.6M$34.9M
Cost and expenses$47.3M$44.3M$49.1M$47.7M$43.7M
Interest income$480K$330K$290K$100K$30K
Interest expense$500K$610K$670K$590K$100K
Depreciation and amortization$5.29M$6.04M$8.1M$5.33M$4.61M
Ebitda$2.96M$180K$2.49M$330K-$-860K
Operating income-$-2.79M-$-6.43M-$-9.55M-$-5.7M-$-7.68M
Total other income/expenses, net-$-30K-$-30K$3.27M$120K$2.12M
Income before tax-$-2.82M-$-6.47M-$-6.28M-$-5.58M-$-5.56M
Income tax expense$40K-$-20K$50K$70K$30K
Net income-$-2.84M-$-6.48M-$-6.28M-$-5.57M-$-3.51M
Weighted average shares outstanding$15M$14.1M$14.3M$14.6M$14.9M
Weighted average diluted shares outstanding$15M$14.1M$14.3M$14.6M$14.9M
Balance sheet
20252024202320222021
Cash and short-term investments$11.4M$18M$18.3M$19.8M$27M
Net receivables$16.9M$11.7M$9.76M$13.2M$6.88M
Inventory$6.23M$4M$4.61M$9.86M$8.43M
Total current assets$37.1M$36.5M$35.7M$45.9M$45.7M
Property, plant and equipment, net$8.61M$6.45M$7.04M$5.5M$1.47M
Goodwill and intangible assets$14.9M$18.9M$23.5M$31.5M$24.8M
Long-term investments$3.99M$0.00$0.00$0.00$0.00
Total non-current assets$39.8M$39.1M$46.1M$47.1M$38.8M
Total assets$76.8M$75.6M$81.8M$92.9M$84.5M
Accounts payable$18.6M$13.9M$14M$10.8M$9.64M
Short-term debt$470K$5.46M$350K$170K$970K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$36.7M$31.6M$28M$28.6M$19.3M
Long-term debt$9.71M$15.1M$18.1M$20.8M$15.1M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$15.5M$21.4M$24.5M$28.4M$22.6M
Capital lease obligations$4.94M$5.3M$5.64M$4.76M$1.06M
Total liabilities$52.3M$53M$52.5M$57M$41.9M
Common stock$51.7M$46.8M$47.1M$47.5M$48.5M
Retained earnings-$-26.8M-$-23.97M-$-17.49M-$-11.21M-$-5.64M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$24.5M$22.6M$29.3M$36M$42.6M
Total investments$3.99M$0.00$0.00$0.00$0.00
Total debt$10.2M$20.6M$18.4M$21M$16.1M
Net debt-$-1.26M$2.61M$110K$1.2M-$-10.98M
Cash flow statement
20252024202320222021
Net income-$-2.86M-$-6.48M-$-6.28M-$-5.65M-$-3.6M
Depreciation and amortization$5.29M$6.04M$5.77M$5.33M$4.61M
Stock-based compensation$410K$300K$370K$450K$740K
Change in working capital$2.16M$1.29M$4.63M$11M$8.18M
Accounts receivable-$-5.24M-$-1.94M$3.4M-$-6.12M$5.5M
Inventory$2.24M$2.41M-$-20K$1.38M$4.82M
Accounts payable$6.71M-$-990K$3.72M$15.1M-$-760K
Net cash provided by operating activities$4.93M-$-610K$6.09M$8.45M$6.34M
Investments in property, plant and equipment-$-180K-$-180K-$-450K-$-2.07M-$-350K
Acquisitions, net$0.00$0.00$0.00-$-13.5M$0.00
Net cash used for investing activities-$-4.71M$60K-$-110K-$-13.67M-$-500K
Common stock issued$5.27M$0.00$0.00$0.00$0.00
Common stock repurchased-$-260K-$-580K-$-740K-$-1.05M-$-1.39M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-6.75M$200K-$-7.42M-$-2.06M-$-3.55M
Net change in cash-$-6.52M-$-360K-$-1.44M-$-7.28M$2.29M
Cash at end of period$11.4M$18M$18.3M$19.8M$27M
Operating cash flow$4.93M-$-610K$6.09M$8.45M$6.34M
Capital expenditure-$-100K-$-180K-$-450K-$-2.07M-$-350K
Free cash flow$4.83M-$-790K$5.64M$6.38M$5.99M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Cumberland Pharmaceuticals Inc.

        Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning. Caldolor: an injectable medication for managing pain and fever. Kristalose: a prescription oral laxative solution effective for chronic and acute constipation. Omeclamox-Pak: used in the treatment of Helicobacter pylori infection and duodenal ulcer disease. Vaprisol: an injectable therapy for euvolemic and hypervolemic hyponatremia. Vibativ: an injectable antibiotic prescribed for severe bacterial infections, including those acquired in hospitals or associated with ventilators, as well as complex skin and skin structure infections. In its development pipeline, Cumberland is advancing: RediTrex injection: designed to treat active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, along with disabling psoriasis. Ifetroban: a product candidate currently in Phase II clinical trials for aspirin-exacerbated respiratory disease, systemic sclerosis, and Duchenne muscular dystrophy. It has also completed Phase II clinical trials for hepatorenal syndrome and portal hypertension, with further clinical investigation ongoing for its potential use in progressive fibrosing interstitial lung diseases. An additional product candidate in Phase II clinical trials, aimed at reducing cholesterol levels for hospital use. Founded in 1999, the company's corporate headquarters are located in Nashville, Tennessee.

        CEO
        A. J. Kazimi
        Employees
        93
        Beta
        0.11

        Explore

        Frequently asked questions

        What is the intrinsic value of Cumberland Pharmaceuticals Inc. (CPIX)?

        InvestorsCraft does not currently publish an intrinsic value for CPIX. How the IC value is calculated.

        Is CPIX undervalued?

        InvestorsCraft does not publish an undervaluation signal for CPIX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.